title: Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs.
abstract: Previous studies have shown that several vasoactive drugs can selectively reduce blood flow and increase hypoxia in experimental tumor systems. Our studies with one such agent, the vasodilator hydralazine, have clearly demonstrated that it can increase the tumor cytotoxicity of drugs which are known to be more toxic under hypoxic conditions. We have now extended our investigations to determine whether such selective reductions in tumor blood flow induced by hydralazine can increase the tumor cytotoxicity of other classes of cancer chemotherapeutic drugs. Our initial studies have involved the alkylating agent melphalan. Administration of hydralazine (5 mg/kg IP) at various times before or after melphalan results in increased tumor cytotoxicity in the Lewis lung carcinoma. An enhancement factor of between 2 and 3 was obtained in this tumor system. Similar results are observed if the vasodilator cadralazine is used. In contrast to the enhancement of the tumor cytotoxicity of melphalan by hydralazine, systemic toxicity is only increased by a factor of 1.2. Therefore, therapeutic gain may accrue from the use of vasodilating agents in combination with melphalan. Studies using spheroids to establish the mechanism responsible for the enhanced tumor cytotoxicity indicate that both hypoxia and pH can influence melphalan toxicity.
authors.affiliation: Medical Biophysics Unit, B.C. Cancer Research Centre, Vancouver, Canada.
authors.forename: D J
authors.initials: DJ
authors.lastname: Chaplin
authors.forename: B
authors.initials: B
authors.lastname: Acker
authors.forename: P L
authors.initials: PL
authors.lastname: Olive
mesh_terms: D000818:Animals; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006830:Hydralazine / Q000627:therapeutic use; D008558:Melphalan / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D011724:Pyridazines / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D011724:Pyridazines; D014665:Vasodilator Agents; D006830:Hydralazine; C031877:cadralazine; D008558:Melphalan